Peripheral DES Presents Copious Early-Stage Reg Requirements – CDRH Staff
This article was originally published in The Gray Sheet
FDA is warning peripheral drug-eluting stent manufacturers not to underestimate the utility of collaborating with the agency early in the preclinical process
You may also be interested in...
FDA's revised target for medical device review times would yield a nearly 10% reduction in total FDA days for half the premarket applications approved between fiscal 2005 and 2007
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.